Core Viewpoint - Akanda Corp. plans to implement a 1-for-40 reverse stock split effective May 23, 2024, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][2]. Company Overview - Akanda Corp. is an international medical cannabis company focused on improving access to high-quality and affordable products [3]. - The company's portfolio includes CanMart, a UK-based licensed pharmaceutical importer and distributor, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic in the UK [3]. - Akanda has acquired rights to develop a farming property in British Columbia, Canada, for THC and cannabinoid (CBD) facilities [3]. Reverse Stock Split Details - The reverse stock split will convert every 40 shares into one share, with no fractional shares issued; any fractions will be rounded down [2]. - This action was approved by the company's board of directors and shareholders, and the company will file Articles of Amendment with the Ontario Ministry of Government and Consumer Services [2]. - The new CUSIP number for the ordinary shares post-split will be 00971M304 [1].

Company Overview - Akanda Corp. is an international medical cannabis company focused on improving access to high-quality and affordable products [6] - The company's portfolio includes CanMart, a UK-based licensed pharmaceutical importer and distributor, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic in the UK [6] Offering Details - Akanda has closed its second registered direct offering, selling 2,491,381 common shares at a price of $0.1031 and 12,057,600 pre-funded warrants at $0.103 per share [2] - The gross proceeds from this offering were approximately $1,500,000, which will be used for capital expenditures, operating capacity, working capital, general corporate purposes, and refinancing existing debt [3] Regulatory Compliance - The securities were offered under an effective shelf registration statement on Form F-3, which was declared effective on January 29, 2024 [4] - The final prospectus supplement related to the offering was filed with the SEC on May 20, 2024, and is available on the SEC's website [4]

Core Points - Akanda Corp has successfully closed a registered direct offering, selling 2,491,381 common shares at $0.1031 each and 21,756,922 pre-funded warrants at $0.103 each, generating gross proceeds of approximately $2,500,000 [2][3]. Group 1: Offering Details - The offering included 2,491,381 common shares and 21,756,922 pre-funded warrants, with the warrants being immediately exercisable at $0.0001 per share [2][3]. - The offering was conducted under an effective shelf registration statement filed with the SEC, which was declared effective on January 29, 2024 [4]. Group 2: Use of Proceeds - Akanda intends to utilize the net proceeds for capital expenditures, enhancing operating capacity, working capital, general corporate purposes, and refinancing or repaying existing debt [3]. Group 3: Company Overview - Akanda is an international medical cannabis company focused on improving access to high-quality and affordable products, with a portfolio that includes CanMart, a licensed pharmaceutical importer and distributor in the UK [6]. - The company is also developing a Canadian farming property in British Columbia for THC and cannabinoid (CBD) production [6].

Core Viewpoint - Akanda Corp. has announced a registered direct offering to raise approximately $2.5 million through the sale of common shares and pre-funded warrants, aimed at general working capital and corporate expenses [2][3]. Group 1: Offering Details - The offering includes 2,491,381 common shares priced at $0.1031 each and 21,756,922 pre-funded warrants at $0.103 per share, with the warrants being immediately exercisable at $0.0001 [2]. - The gross proceeds from the offering are estimated to be around $2,500,000 before deducting fees and expenses [3]. - The offering is expected to close on or about May 17, 2024, pending customary closing conditions [3]. Group 2: Regulatory Information - The offering is conducted under an effective shelf registration statement on Form F-3, previously filed with the SEC and effective since January 29, 2024 [4]. - A final prospectus related to the offering will be filed with the SEC and will be available for free on the SEC's website [4]. Group 3: Company Overview - Akanda Corp. is an international medical cannabis company focused on improving access to high-quality and affordable products [6]. - The company's portfolio includes CanMart, a licensed pharmaceutical importer and distributor in the UK, and partnerships with Cellen Life Sciences' Leva Clinic [6]. - Akanda is also developing a Canadian farming property in British Columbia for THC and CBD facilities [6].

Core Points - Akanda Corp (NASDAQ: AKAN) received a notice of non-compliance from Nasdaq due to failing to meet the minimum stockholders' equity requirement as per Nasdaq Listing Rule 5550(b)(1) [2] - The company also did not satisfy alternative compliance standards based on market value of listed securities or net income from continuing operations [2] - Akanda's stock experienced a significant decline in short interest, with shares sold short decreasing by 66.1% from April 15th to April 30th [2] Compliance Plan - Akanda is required to submit a plan to regain compliance by June 28th [4] - If the plan is accepted, the company may receive an extension of up to 180 days from Nasdaq to implement its proposal [4] - The CEO of Akanda expressed confidence in submitting a viable plan and emphasized the company's commitment to regaining compliance [4]

Core Points - Akanda Corp. has received a deficiency notification from Nasdaq for non-compliance with the minimum stockholders' equity requirement of $2,500,000, as its reported stockholders' equity was ($3,828,892) for the fiscal year ended December 31, 2023 [2][3] - The company has 45 calendar days, until June 28, 2024, to submit a plan to regain compliance, with the possibility of an extension of up to 180 days if the plan is accepted [3] - Akanda is currently evaluating options to resolve the deficiency and intends to submit a comprehensive plan within the stipulated timeframe [3] - The company's common shares will continue to trade on the Nasdaq Capital Market under the symbol "AKAN" despite the notification [3] - Interim CEO Katie Field emphasized the company's commitment to addressing the compliance issue and appreciated investor support during this period [3] Company Overview - Akanda Corp. is an international medical cannabis and wellness platform company focused on improving access to high-quality and affordable products [4] - The company's portfolio includes CanMart, a UK-based licensed pharmaceutical importer and distributor, and partnerships with Cellen Life Sciences' Leva Clinic, a digital pain clinic in the UK [4] - Akanda has acquired rights to develop a Canadian farming property in British Columbia for THC and cannabinoid (CBD) facilities [4]

Acquisitions and Sales - Akanda Corp. completed the acquisition of Cannahealth Limited on November 3, 2021, issuing 1,312,921 Common Shares at $10.00 per share, resulting in Halo owning approximately 68.3% of outstanding shares [171]. - The Holigen Acquisition closed on April 29, 2022, for a total consideration of $3,000,000 in cash and 190,000 Common Shares [175]. - On February 28, 2024, Akanda entered into a share purchase agreement to sell RPK for $2,000,000, completing the transaction on April 1, 2024 [189]. - The Company completed the sale of RPK to Somai Pharmaceuticals for a cash purchase price of $2,000,000, with Somai assuming approximately €4,000,000 in liabilities [206]. - The Company completed the transaction with Somai for the sale of RPK in April 2024, resulting in the discontinuation of previous cooperation agreements [216]. Financial Performance - Revenue decreased to $2,160,052 in 2023 from $2,619,682 in 2022, attributed to higher sales discounts and returns [281]. - Cost of sales increased significantly from $566,252 in 2022 to $1,908,515 in 2023, reflecting increased sales activities and marketing efforts [282]. - Gross profit fell to $111,449 in 2023 compared to $3,269,559 in 2022, impacted by the loss on the change in fair value of biological assets [283]. - Operating loss improved to $(10,051,373) in 2023 from $(20,176,389) in 2022, despite overall losses [291]. - Net loss from continuing operations was $(32,275,070) in 2023, compared to $(8,235,449) in 2022, primarily due to an impairment loss of $24,665,564 [291]. - Cash used by operating activities was $(1,500,574) in 2023, a decrease of $9,968,822 from $(11,469,396) in 2022 [295]. - Cash provided by financing activities was $1,486,567 in 2023, a significant change from $(12,652,069) in 2022 [295]. Capital Raising and Financing - The company raised approximately $708,000 from a registered direct offering of 280,851 Common Shares at $0.406 per share on February 2, 2024 [190]. - A subsequent registered direct offering on March 4, 2024, raised approximately $150,000 from the sale of 367,870 Common Shares at $0.20544 per share [191]. - In a subsequent underwritten public offering, the Company sold 3,087,443 Common Shares at $0.1217 per share and pre-funded warrants for 37,997,190 Common Shares, generating gross proceeds of $5,000,000 before expenses, with 20,085,234 pre-funded warrants exercised [193]. - The Company issued 280,851 common shares at $0.406 per share and 1,462,991 pre-funded warrants for gross proceeds of $708,000 on February 2, 2024 [307]. - On March 24, 2024, the Company entered into an underwriting agreement for the issuance of 3,087,443 common shares at $0.1217 per share, raising gross proceeds of $5,000,000 [312]. Operations and Production - Akanda's facilities in Portugal can produce approximately seven tonnes of high-THC cannabis annually, with THC levels consistently around 25% [176]. - RPK operates a 20,000 square foot indoor EU GMP certified grow facility in Portugal, yielding over 2,000 kg of premium cannabis flower annually, with over 25% of its production sold in Germany [204]. - The Company has established a partnership with Cansativa Group to supply the German market with dried flowers from its EU-GMP certified facility in Portugal [214]. - Canmart has successfully imported over 100 kg of cannabis products for distribution in the UK, operating under a Controlled Drug License [200]. - The Company plans to develop THC and CBD facilities in British Columbia, having made an initial non-refundable payment of $1,800,000 for the farming property [208]. Regulatory and Compliance - A Controlled Drug License is required for companies wishing to possess, supply, or produce controlled drugs, with licenses issued for specific drugs and locations [222]. - The U.K. Food Standards Agency regulates the sale of CBD products, which must comply with the Novel Food Regulation for safety and labeling [233][234]. - The Novel Food Regulation requires that a food product must not have been used for human consumption to a significant degree within the EU before May 15, 1997, to be classified as "novel" [235]. - Health Canada oversees the licensing process for cannabis-related activities, with no guaranteed timelines for application reviews [250]. - Security clearances are required for individuals in key positions within cannabis licensees, with the Minister of Health having discretion over approvals [251]. Corporate Governance and Management - The Company approved a new 30% evergreen 2024 Equity Incentive Plan during the annual shareholder meeting held on March 22, 2024 [194]. - The audit committee consists of three independent directors, ensuring compliance with Nasdaq standards [351]. - The compensation committee is responsible for evaluating executive performance and recommending compensation [352]. - The company follows Canadian corporate governance practices, which may differ from Nasdaq requirements [340]. - The company did not hold its annual shareholders meeting in fiscal year 2023, complying with a court order [347]. Employee and Executive Compensation - Total compensation for executive officers decreased from $2,656,958 in 2022 to $520,298 in 2023, a reduction of approximately 80.4% [330]. - The total compensation for the former Chief Executive Officer was $1,469,111 in 2022, significantly higher than the current interim CEO's compensation of $111,968 in 2023 [330]. - Non-executive directors will receive an annual retainer of $75,000, with additional compensation for committee service [331]. - The company has a total of 5 employees as of April 29, 2024 [361]. Miscellaneous - The Company is still in the startup phase and unable to identify recent trends in revenue or expenses [317]. - The Company has a new Chief Financial Officer, Gurcharn Deol, who has over 35 years of public company management experience [326]. - The Company entered into a settlement agreement for £30,000 with the former SVP of Finance to settle claims [316]. - A claim of CAD $271,990 was filed by the former CFO for unpaid salary and invoices, which the Company disputes [315].

As filed with the Securities and Exchange Commission on March 15, 2024 Registration No. 333-277182 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ AMENDMENT NO.2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ________________________ Akanda Corp. (Exact name of Registrant as specified in its charter) ________________________ | Ontario, Canada | 2833 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standa ...

As filed with the Securities and Exchange Commission on March 11, 2024 Registration No. 333-277182 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ AMENDMENT NO.1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ________________________ Akanda Corp. (Exact name of Registrant as specified in its charter) ________________________ | Ontario, Canada | 2833 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standa ...

________________________ Akanda Corp. As filed with the Securities and Exchange Commission on February 20, 2024 Registration No. 333-_______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Exact name of Registrant as specified in its charter) ________________________ | | | (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificat ...